Corona Remedies Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
CORONA Remedies reported Q1 FY27 revenue growth of 21.9% year-on-year to Rs 422 crores, with EBITDA growing 33.5% and PAT growing 30.1%. Management said the India business grew 22.7%, outperforming the Indian Pharmaceutical Market's 11.6% growth, driven by a mix of volume, pricing and new product launches. The company also commercialized a new EU-GMP approved hormone manufacturing facility during the quarter and reaffirmed its FY27 revenue and profit growth targets.
CORONA Remedies reported FY26 revenue growth of 17.3% year-on-year to INR 1,403 crores and PAT growth of 33.4%, exceeding its guided range of 15% revenue and 20% PAT growth. Q4FY26 revenue grew 20.2% to INR 353 crores while EBITDA margin declined about 90bps to 17.6% due to higher employee and R&D costs from new division launches. Management discussed the Wokadine and Bayer portfolio acquisitions, entry into biosimilars with Semaglutide launches, and plans for manufacturing capacity expansion including a new hormone plant expected to become operational in Q1 or Q2 of FY27.